9results about How to "Reduce immune rejection" patented technology

The invention is applicable to the technical field of hemodialyzers, and provides a hollow fiber membrane hemodialyzer with a gradient aperture structure, which comprises a shell, a hollow fiber membrane bundle packaged in the shell, an end cover and a sealing component, the hollow fiber membrane bundle is composed of a plurality of gradient aperture hollow fiber membranes; the hollow fiber membrane is of a two-way gradient aperture structure along the membrane thickness direction; a compact screening layer and a loose transition layer are sequentially arranged on the inner wall of the hollow fiber membrane; a loose diffusion layer and a compact protective layer are sequentially arranged on the outer side of the hollow fiber membrane; the pore diameter of the compact protective layer is not greater than 30nm; the porosity of the hollow fiber membrane is synchronously and progressively increased along with the aperture gradient, the porosity range is 40%-80%, the dialyzer has the characteristics of bidirectional gradient aperture optimization design, gradient functional coating protection, modular adaptation, special-shaped section synergy and the like, and the technical problems that an existing dialyzer is incomplete in toxin removal, insufficient in safety and the like are solved.

The invention discloses an application of engineered citrobacter freundii in fermentation synthesis of a stable body. The engineered citrobacter freundii is citrobacter freundii overexpressing a polyphosphate kinase gene Ppk1. The stable body prepared by fermenting the engineered citrobacter freundii is rich in polyphosphates and polyamines, particularly, the content of the polyamines can be up to 21wt%, the polyphosphates in the stable body can store the polyamines in an ionic bond combination mode, the combined polyamines are insoluble in water, a natural anion coating is generated, and the stability of the stable body is improved. And the sustained-release tablet is not easily taken by intestinal epithelial cells, so that the sustained-release tablet has a certain sustained-release effect. The medicine prepared by taking the compound as a main active ingredient shows a remarkable curative effect in ulcerative colitis treatment, has the comprehensive effects of reducing oxidative stress, enhancing the anti-inflammatory ability of a body and regulating immunity, is suitable for patients of all ages, and has outstanding application value and market prospect.

The invention provides composite hydrogel for promoting tissue regeneration and repair as well as a preparation method and application of the composite hydrogel, and belongs to the field of hydrogel materials. The method comprises the following steps: carrying out anhydride aminolysis ring-opening reaction on a styrene-maleic anhydride alternating copolymer, amino polyethylene glycol methyl ether, 3-aminophenylboronic acid and cysteamine hydrochloride; the preparation method comprises the following steps: carrying out a first amidation reaction on GRGDS pentapeptide and an SPDP cross-linking agent, then carrying out a disulfide bond exchange reaction on the obtained product and GPLGIAGQ-PEG-SH, and finally carrying out a second amidation reaction on the obtained product and 3-maleimide propionic acid-NHS ester; the preparation method comprises the following steps: carrying out a modification reaction on a PEDOT: PSS aqueous dispersion and 3-aminopropyltriethoxysilane; the preparation method comprises the following steps: mixing a multifunctional polymer, a signal molecule, a conductive component, four-arm PEG-hydrazide and oxidized sodium alginate, and sequentially carrying out physical gelation and chemical crosslinking to obtain the composite hydrogel. Therefore, the intelligent responsiveness, the biological activity and the conductivity of the hydrogel are synergistically improved.

The application discloses an ACVR2A antibody and application thereof, and relates to the technical field of biological medicine. The antibody provided by the application has the advantages of stronger affinity to ACVR2A and higher selectivity to ACVR2A, and provides diversified treatment options for different clinical requirements and expands the application potential of ACVR2A targeted treatment.

This invention discloses a method for preparing antler-DCB bone graft scaffold material, specifically: S1, cutting cancellous bone from antlers into bone samples and treating them with ultrasound; S2, immersing the samples in ethanol and shaking on a shaker; S3, immersing the samples in ether and shaking on a shaker; S4, immersing the samples in sodium hydroxide solution and shaking on a shaker, then rinsing the bone samples with running water, treating them with 30% hydrogen peroxide for 24 hours, and rinsing them again; S5, placing the rinsed bone samples in a 3:1 mixture of chloroform and methanol for 1 hour, rinsing them with distilled water, and drying them at 70°C for 1 day to obtain the antler-DCB bone graft scaffold material. This invention also discloses the antler-DCB bone graft scaffold material. The antler-DCB bone graft scaffold material and its preparation method disclosed in this invention have high porosity, large pore size, and specific surface area, which are more conducive to bone regeneration.

The invention discloses a 3D printing cavernous body organ-like model capable of simulating an erectile physiological process, and belongs to the technical field of tissue engineering and regenerative medicine. The hydrogel is formed by photo-curing 3D printing of a dual-network hydrogel material formed by blending a pig cavernous body acellular extracellular matrix pregel solution and polyethylene glycol diacrylate, and has a bionic sine curve expansion structure; micron-sized grooves for guiding the directional arrangement of smooth muscle cells are formed in the surface of the micro-sphere, and an elliptical cavity for providing structural support is formed in the micro-sphere. A pig cavernous body dECM pre-gel solution is used as a base material, so that a microenvironment for living of cells in a body can be effectively simulated; by regulating and controlling the proportion of PEGDA, the mechanical property of the model is matched with that of a natural cavernous body tissue. The organ model can reproduce the NO-mediated smooth muscle cell relaxation and tissue expansion physiological process in vitro, and provides an effective in-vitro platform for researching the pathological mechanism of erectile dysfunction, screening drugs and developing a novel treatment method.

This invention belongs to the field of antibody technology, specifically relating to an IL13Rα2 nanobody targeting IL13Rα2, a chimeric immune receptor, and their applications and products. This invention is the first to discover an IL13Rα2 nanobody with a specific complementarity-determining region amino acid sequence. The nanobody possesses advantages such as high affinity, high specificity, low immunogenicity, small molecular weight, and strong tissue penetration. This invention also provides a chimeric immune receptor comprising the nanobody, recombinant protein, nucleic acid molecule, expression vector, engineered immune cells, antibody preparation, kit, and pharmaceutical composition. CAR-T cells constructed based on the nanobody exhibit highly efficient and specific killing ability against IL13Rα2-positive tumor cells and can effectively overcome tumor antigen heterogeneity. They can be used to prepare drugs or kits for the diagnosis or treatment of IL13Rα2-related diseases, showing promising clinical application prospects.

The present application relates to the technical field of nanobody, in particular to anti-FcRH5 nanobody and its application. The present application provides a kind of anti-FcRH5 nanobody with high affinity and specificity, which is based on the single domain heavy chain variable region structure of camelid origin, with the advantages of small molecular weight, high stability, strong tissue penetration, easy to be engineered and the like. The nanobody specifically recognizes and binds to the target point highly expressed and stably expressed on the surface of multiple myeloma cells through its complementarity determining region. The nanobody of the present application can be used as a core recognition element to construct a variety of therapeutic or diagnostic tools such as chimeric antigen receptor T cells, bispecific antibodies, antibody drug conjugates or immunodetection probes. The technical scheme can solve the technical problem that there is a lack of high-quality, functionally clear anti-FcRH5 antibody in the prior art. The nanobody of the present application has significant clinical transformation and industrialization advantages, and promotes the treatment of multiple myeloma to multiple target points.

This invention specifically discloses an ACVR2A antibody and its applications, relating to the field of biomedical technology. The antibody provided by this invention has a stronger affinity for and higher selectivity for ACVR2A, offering diverse treatment options for different clinical needs and expanding the application potential of ACVR2A-targeted therapy.